Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →HH160 is a novel trispecific antibody developed by Huahui Health using its proprietary PolyBoost multispecific antibody platform that simultaneously targets…
BeOne Medicines is the latest oncology developer to bet on a Chinese-discovered multispecific antibody, taking a global exclusive option on Huahui Health's…
BeOne Medicines, the Switzerland-redomiciled oncology biopharma formerly known as BeiGene, has agreed to pay Huahui Health up to USD 2.02 billion for an…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
BeOne Medicines entered a global exclusive option, license and collaboration agreement with China-based Huahui Health for trispecific antibody HH160; $20M upfront, $100M option-exercise payment, and up to $1.9B in development/regulatory/commercial milestones, totaling ~$2.02B excluding royalties.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| BeOne Medicines Ltd. / Huahui Health Ltd. (this deal) | 2026 | $2.0B | — |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Astellas Pharma Inc. / Seagen Inc. | 2009 | $4.5B | 95 |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
| Servier / Agios Pharmaceuticals (oncology) | 2020 | $2.0B | 91 |
| Servier Pharmaceuticals LLC / Agios Pharmaceuticals Inc. | 2020 | $2.0B | 91 |
← Browse all deals · How we score deals
More: 2026 deals · Oncology deals